| Revision as of 21:46, 6 September 2011 edit58.178.233.130 (talk)No edit summary← Previous edit |
Latest revision as of 00:59, 13 September 2024 edit undoGraeme Bartlett (talk | contribs)Administrators249,716 edits more ids |
| (13 intermediate revisions by 11 users not shown) |
| Line 1: |
Line 1: |
|
|
{{Short description|Monoclonal antibody}} |
|
{{Drugbox |
|
{{Drugbox |
|
|
| Verifiedfields = changed |
|
| verifiedrevid = 422323757 |
|
| verifiedrevid = 448818654 |
|
|
|
|
<!--Monoclonal antibody data--> |
|
<!-- Monoclonal antibody data --> |
|
| type = mab |
|
| type = mab |
|
| mab_type = |
|
| mab_type = |
|
| source = u |
|
| source = u |
|
| target = ] |
|
| target = ] |
|
⚫ |
<!-- Clinical data --> |
|
|
|
|
|
| tradename = |
| ⚫ |
<!--Clinical data--> |
|
|
| tradename = |
|
| pregnancy_AU = |
|
| pregnancy_AU = |
|
| pregnancy_US = |
|
| pregnancy_US = |
|
|
| pregnancy_category = N/A |
|
| pregnancy_category = N/A |
|
| legal_AU = |
|
| legal_AU = |
|
| legal_CA = |
|
| legal_CA = |
|
| legal_UK = |
|
| legal_UK = |
|
| legal_US = |
|
| legal_US = |
|
| legal_status = Investigational (animal studies) |
|
| legal_status = Investigational (animal studies) |
|
| routes_of_administration = |
|
| routes_of_administration = |
|
⚫ |
<!-- Pharmacokinetic data --> |
|
|
|
|
|
| bioavailability = |
| ⚫ |
<!--Pharmacokinetic data--> |
|
|
| bioavailability = |
|
| protein_bound = |
|
| protein_bound = |
|
| metabolism = |
|
⚫ |
| elimination_half-life = |
|
| metabolism = |
|
|
⚫ |
| excretion = |
| ⚫ |
| elimination_half-life = |
|
|
⚫ |
<!-- Identifiers --> |
| ⚫ |
| excretion = |
|
|
⚫ |
| CAS_number = |
|
|
|
| ⚫ |
<!--Identifiers--> |
|
| ⚫ |
| CAS_number = |
|
|
| ATC_prefix = none |
|
| ATC_prefix = none |
|
| ATC_suffix = |
|
| ATC_suffix = |
|
|
| PubChemSubstance = 194161622 |
|
| PubChem = |
|
|
|
| ChEMBL = 3137350 |
|
| DrugBank_Ref = {{drugbankcite|correct|drugbank}} |
|
| DrugBank_Ref = {{drugbankcite|correct|drugbank}} |
|
| DrugBank = |
|
| DrugBank = |
|
|
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}} |
|
|
|
|
|
| ChemSpiderID = none |
|
<!--Chemical data--> |
|
<!-- Chemical data --> |
|
| chemical_formula = |
|
| chemical_formula = |
|
|
|
|
| molecular_weight = |
|
| molecular_weight = |
|
}} |
|
}} |
|
'''CR6261''' is a ]<ref>{{cite doi|10.1371/journal.pone.0009106}}</ref> that binds to a broad range of the ] including the 1918 "]" (SC1918/H1) and to a virus of the ] class of avian influenza that jumped from chickens to a human in Vietnam in 2004 (Viet04/H5). In contrast to most antibodies generated by exposure to influenza, which can only neutralize a few strains from within a single virus subtype, CR6261 neutralizes numerous strains from multiple subtypes. CR6261 recognizes a highly conserved helical region in the membrane-proximal stem of ], the predominant protein on the surface of the ]. Based upon the conservation of the amino acid sequence on this part of hemagglutinin, CR6261 is predicted to neutralize roughly 50% of all flu viruses. It was found by ] and the Dutch biopharmaceutical company, ]. |
|
'''CR6261''' is a ]<ref>{{cite journal | vauthors = Friesen RH, Koudstaal W, Koldijk MH, Weverling GJ, Brakenhoff JP, Lenting PJ, Stittelaar KJ, Osterhaus AD, Kompier R, Goudsmit J | display-authors = 6 | title = New class of monoclonal antibodies against severe influenza: prophylactic and therapeutic efficacy in ferrets | journal = PLOS ONE | volume = 5 | issue = 2 | pages = e9106 | date = February 2010 | pmid = 20161706 | pmc = 2817000 | doi = 10.1371/journal.pone.0009106 | bibcode = 2010PLoSO...5.9106F | editor1-last = Zhang | editor1-first = Linqi | doi-access = free }}</ref> that binds to a broad range of the ] including the 1918 "]" (SC1918/H1) and to a virus of the ] class of avian influenza that jumped from chickens to a human in Vietnam in 2004 (Viet04/H5). In contrast to most antibodies generated by exposure to influenza, which can only neutralize a few strains from within a single virus subtype, CR6261 neutralizes numerous strains from multiple subtypes. CR6261 recognizes a highly conserved helical region in the membrane-proximal stem of ], the predominant protein on the surface of the ]. Based upon the conservation of the amino acid sequence on this part of hemagglutinin, CR6261 is predicted to neutralize roughly 50% of all flu viruses. It was found by ] and the Dutch biopharmaceutical company, ]. |
|
|
|
|
|
==See also== |
|
== See also == |
|
* ] |
|
* ] |
|
|
|
|
|
==References== |
|
== References == |
|
{{reflist}} |
|
{{reflist}} |
|
|
|
| ⚫ |
*Research team finds immune molecule that attacks wide range of flu viruses |
|
|
|
== Further reading == |
| ⚫ |
*Immune Molecule That Attacks Wide Range Of Flu Viruses Discovered |
|
|
|
{{refbegin}} |
|
*Antibody Recognition of a Highly Conserved Influenza Virus Epitope |
|
|
⚫ |
* {{cite web | title = Research team finds immune molecule that attacks wide range of flu viruses | url = http://www.physorg.com/news154880861.html | work = physorg.com | date = 26 February 2009 }} |
|
⚫ |
* {{cite web | title = Immune Molecule That Attacks Wide Range Of Flu Viruses Discovered | url = https://www.sciencedaily.com/releases/2009/02/090226141118.htm | work = ScienceDaily | date = 27 February 2009}} |
|
|
* {{cite journal | vauthors = Ekiert DC, Bhabha G, Elsliger MA, Friesen RH, Jongeneelen M, Throsby M, Goudsmit J, Wilson IA | title = Antibody recognition of a highly conserved influenza virus epitope | journal = Science | location = New York, N.Y. | volume = 324 | issue = 5924 | pages = 246–51 | date = April 2009 | pmid = 19251591 | pmc = 2758658 | doi = 10.1126/science.1171491 | bibcode = 2009Sci...324..246E }} |
|
|
{{refend}} |
|
|
|
|
|
] |
|
] |
|
] |
|
|
] |
|
] |
|
|
|
|
|
{{monoclonal-antibody-stub}} |
|
{{monoclonal-antibody-stub}} |
|
{{antiinfective-drug-stub}} |
|
{{antiinfective-drug-stub}} |
|
|
|
|
] |
|